| Sequence 1: | XP_016882868.1 | Gene: | FBN3 / 84467 | HGNCID: | 18794 | Length: | 2851 | Species: | Homo sapiens |
|---|---|---|---|---|---|---|---|---|---|
| Sequence 2: | NP_032019.2 | Gene: | Fbn1 / 14118 | MGIID: | 95489 | Length: | 2873 | Species: | Mus musculus |
| Alignment Length: | 2908 | Identity: | 1756/2908 - (60%) |
|---|---|---|---|
| Similarity: | 2181/2908 - (75%) | Gaps: | 101/2908 - (3%) |
- Green bases have known domain annotations that are detailed below.
|
Human 8 LARGPLARLLLAWSALLCMAGGQGRWDGALEAAG-----PGRVRRRGSPG--ILQGPNVCGSRFH 65
Human 66 AYCCPGWRTFPGRSQCVVPICRRACGEGFCSQPNLCTCADGTLAPSCGVSRGSGCSVSCMNGGTC 130
Human 131 RGASCLCQKGYTGTVCGQPICDRGCHNGGRCIGPNRCACVYGFMGPQCERDYRTGPCFGQVGPEG 195
Human 196 CQHQLTGLVCTKALCCATVGRAWGLPCELCPAQPHPCRRGFIPNIHTGACQDVDECQAVPGLCQG 260
Human 261 GSCVNMVGSFHCRCPVGHRLSDSSAACEDVNECLSLSGLCSGGDCTNTVGSYVCTCSQGFASSLD 325
Human 326 GTHCLNYRAGACFSVLFGGRCAGDLAGHYTRRQCCCDRGRCWAAG--PVPELCPPRGSNEFQQLC 388
Human 389 AQRLPL-LPGHPGLFPGLLGFGSNGMGPPLG----------------------PARLNPHGSDAR 430
Human 431 GIPSLGPGNSNIGTATLNQTIDICRHFTNLCLNGRCLPTPSSYRCECNVGYTQDVRGECIDVDEC 495
Human 496 TSSPCHHGDCVNIPGTYHCRCYPGFQATPTRQACVDVDECIVSGGLCHLGRCVNTEGSFQCVCNA 560
Human 561 GFELSPDGKNCVDHNECATSTMCVNGVCLNEDGSFSCLCKPGFLLAPGGHYCMDIDECQTPGICV 625
Human 626 NGHCTNTEGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKGSCARPFPGTVTKSECCCANPD 690
Human 691 HGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECALDPEVCANGVCENLRGSYRCVCNLGY 755
Human 756 EAGASGKDCTDVDECALNSLLCDNGWCQNSPGSYSCSCPPGFHFWQDTEICKDVDECLSSPCVSG 820
Human 821 VCRNLAGSYTCKCGPGSRLDPSGTFCLDSTKGTCWLKIQESRCEVNLQGASLRSECCATLGAAWG 885
Human 886 SPCERCEIDPACARGFARMTGVTCDDVNECESFPGVCPNGRCVNTAGSFRCECPEGLMLDASGRL 950
Human 951 CVDVRLEPCFLRWDEDECGVTLPGKYRMDVCCCSIGAVWGV-ECEACPDPESLEFASLCPRGLGF 1014
Human 1015 ASRDFLSGRPFYKDVNECKVFPGLCTHGTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPD 1079
Human 1080 LCGQGTCVNTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNTDGSYKCQCPPGH 1144
Human 1145 ELTAKGTACEDIDECSLSDGLCPHGQCVNVIGAFQCSCHAGFQSTPDRQGCVDINECRVQNGGCD 1209
Human 1210 VHCINTEGSYRCSCGQGYSLMPDGRACADVDECEENPRVCDQGHCTNMPGGHRCLCYDGFMATPD 1274
Human 1275 MRTCVDVDECDLNPHICLHGDCENTKGSFVCHCQLGYMVRKGATGCSDVDECEVGGHNCDSHASC 1339
Human 1340 LNIPGSFSCRCLPGWVGDGFECHDLDECVSQEHRCSPRGDCLNVPGSYRCTCRQGFAGDGFFCED 1404
Human 1405 RDECAENVDLCDNGQCLNAPGGYRCECEMGFDPTEDHRACQDVDECAQGNLCAFGSCENLPGMFR 1469
Human 1470 CICNGGYELDRGGGNCTDINECADPVNCINGVCINTPGSYLCSCPQDFELNPSGVGCVDTRAGNC 1534
Human 1535 FLETHDRGDSG-ISCSAEIGVGVTRASCCCSLGRAWGNPCELCPMANTTEYRTLCPGGEGFQPNR 1598
Human 1599 ITVILEDIDECQELPGLCQGGDCVNTFGSFQCECPPGYHLSEHTRICEDIDECSTHSGICGPGTC 1663
Human 1664 YNTLGNYTCVCPAEYLQVNGGNNCMDMRKSVCFRHY---NGTCQNELAFNVTRKMCCCSYNIGQA 1725
Human 1726 WNRPCEACPTPISPDYQILCGNQAPGFLTDIHTGKPLDIDECGEIPAICANGICINQIGSFRCEC 1790
Human 1791 PAGFNYNSILLACEDVDECGSRESP-CQQNADCINIPGSYRCKCTRGYKLSPGGACVGRNECREI 1854
Human 1855 PNVCSHGDCMDTEGSYMCLCHRGFQASADQTLCMDIDECDRQPCGNGTCKNIIGSYNCLCFPGFV 1919
Human 1920 VTHNGDCVDFDECTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNCVDTNECLSLAGTCLP 1984
Human 1985 GTCQNLEGSFRCICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSPGSFQCLCPPGFVLSDNGH 2049
Human 2050 RCFDTRQSFCFTRFEAGKCSVPKAFNTTKTRCCCSKRPGEGWGDPCELCPQEGSAAFQELCPFGH 2114
Human 2115 GAVPGPDDSREDVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFTGINCVDTDECSVGHPCG 2179
Human 2180 QGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCAFRCHNTEGSYLCTCPAGYTLREDG 2244
Human 2245 AMCRDVDECADGQQDCHARGMECKNLIGTFACVCPPGMRPLPGSGEGCTDDNECHAQPDLCVNGR 2309
Human 2310 CVNTAGSFRCDCDEGFQPSPTLTECHDIRQGPCFAEVLQTMCRSLSSSSEAVTRAECCCGGGRGW 2374
Human 2375 GPRCELCPLPGTSAYRKLCPHGSGYTAEGRDVDECRMLAHLCAHGECINSLGSFRCHCQAGYTPD 2439
Human 2440 ATATTCLDMDECSQVPKPCTFLCKNTKGSFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCV 2504
Human 2505 NTVGAFTCRCPPGFTQHHQACFDNDECSAQPGPCGAHGHCHNTPGSFRCECHQGFTLVSSGHGCE 2569
Human 2570 DVNECDGPHRCQHGCQNQLGGYRCSCPQGFTQHSQWAQCVDENECALSPPTCGSASCRNTLGGFR 2634
Human 2635 CVCPSGFDFDQALGGCQEVDECAGRRGPCSYSCANTPGGFLCGCPQGYFRAGQGHCVSGLGFSPG 2699
Human 2700 PQDTPDKEEL----LSSEACYECKINGLSPRDRPRRSAHR------------DHQVNLATLDSEA 2748
Human 2749 LLTLGLNLSHLGRAERILELRPALEGLEGRIRYVIVRGNEQGFFRMHHLRGVSSLQLGRRRPGPG 2813
Human 2814 TYRLEVVSHMAGPWGVQPEGQ-----------PGPWGQALRLKVQLQL 2850 |
| Gene | Sequence | Domain | Region | External ID | Identity |
|---|---|---|---|---|---|
| FBN3 | XP_016882868.1 | Fibrillin_U_N | 47..83 | CDD:436338 | 25/37 (68%) |
| TB | 196..>228 | CDD:459903 | 25/31 (81%) | ||
| EGF_CA | 289..329 | CDD:214542 | 22/39 (56%) | ||
| TB | 344..388 | CDD:459903 | 21/45 (47%) | ||
| EGF_CA | 491..521 | CDD:214542 | 15/29 (52%) | ||
| EGF_CA | 531..572 | CDD:214542 | 25/40 (63%) | ||
| EGF_CA | 614..654 | CDD:214542 | 28/39 (72%) | ||
| TB | 669..712 | CDD:459903 | 27/42 (64%) | ||
| EGF_CA | 724..760 | CDD:214542 | 25/35 (71%) | ||
| EGF_CA | 766..798 | CDD:238011 | 21/31 (68%) | ||
| TB | 862..>893 | CDD:459903 | 21/30 (70%) | ||
| EGF_CA | 911..941 | CDD:429571 | 22/29 (76%) | ||
| TB | 966..1008 | CDD:459903 | 21/42 (50%) | ||
| EGF_CA | 1070..1104 | CDD:214542 | 27/33 (82%) | ||
| EGF_CA | 1113..1154 | CDD:214542 | 27/40 (68%) | ||
| FXa_inhibition | 1201..1236 | CDD:464251 | 19/34 (56%) | ||
| EGF_3 | 1326..1361 | CDD:463759 | 21/34 (62%) | ||
| EGF_3 | 1367..1402 | CDD:463759 | 18/34 (53%) | ||
| EGF_CA | 1446..1486 | CDD:214542 | 26/39 (67%) | ||
| EGF_CA | 1487..1518 | CDD:214542 | 20/30 (67%) | ||
| TB | 1548..1588 | CDD:459903 | 29/39 (74%) | ||
| EGF_CA | 1605..1641 | CDD:214542 | 29/35 (83%) | ||
| TB | 1701..1745 | CDD:459903 | 26/43 (60%) | ||
| EGF_CA | 1763..1793 | CDD:429571 | 22/29 (76%) | ||
| vWFA | <1803..1841 | CDD:469594 | 23/38 (61%) | ||
| vWFA | <1842..1884 | CDD:469594 | 25/41 (61%) | ||
| EGF_CA | 1889..1923 | CDD:214542 | 20/33 (61%) | ||
| EGF_CA | 2011..2051 | CDD:214542 | 25/39 (64%) | ||
| TB | 2066..2110 | CDD:459903 | 26/43 (60%) | ||
| EGF_CA | 2126..2156 | CDD:429571 | 19/29 (66%) | ||
| EGF_CA | 2168..2207 | CDD:214542 | 31/38 (82%) | ||
| EGF_CA | 2208..2247 | CDD:214542 | 27/38 (71%) | ||
| EGF_CA | 2249..2281 | CDD:429571 | 19/31 (61%) | ||
| EGF_CA | 2405..2441 | CDD:214542 | 18/35 (51%) | ||
| vWFA | <2445..2485 | CDD:469594 | 26/39 (67%) | ||
| EGF_CA | 2488..2517 | CDD:429571 | 22/28 (79%) | ||
| EGF_CA | 2527..2561 | CDD:238011 | 19/33 (58%) | ||
| EGF_CA | 2570..2600 | CDD:214542 | 24/29 (83%) | ||
| Fbn1 | NP_032019.2 | Fibrillin_U_N | 48..82 | CDD:436338 | 22/33 (67%) |
| TB | 194..>227 | CDD:459903 | 25/32 (78%) | ||
| EGF_CA | 246..>276 | CDD:214542 | 22/29 (76%) | ||
| EGF_CA | 288..329 | CDD:214542 | 22/40 (55%) | ||
| TB | 343..389 | CDD:459903 | 21/45 (47%) | ||
| EGF_CA | 492..523 | CDD:214542 | 15/30 (50%) | ||
| EGF_CA | 532..573 | CDD:214542 | 25/40 (63%) | ||
| EGF_CA | 574..614 | CDD:214542 | 24/39 (62%) | ||
| EGF_CA | 615..648 | CDD:214542 | 22/32 (69%) | ||
| TB | 670..713 | CDD:459903 | 27/42 (64%) | ||
| EGF_CA | 767..>798 | CDD:214542 | 20/30 (67%) | ||
| TB | 862..>892 | CDD:459903 | 20/29 (69%) | ||
| TB | 968..1010 | CDD:459903 | 21/41 (51%) | ||
| EGF_CA | 1072..1106 | CDD:214542 | 27/33 (82%) | ||
| EGF_CA | 1115..1151 | CDD:214542 | 26/35 (74%) | ||
| EGF_CA | 1157..1192 | CDD:238011 | 20/34 (59%) | ||
| FXa_inhibition | 1203..1238 | CDD:464251 | 19/34 (56%) | ||
| EGF_3 | 1328..1363 | CDD:463759 | 21/34 (62%) | ||
| EGF_3 | 1369..1404 | CDD:463759 | 18/34 (53%) | ||
| EGF_CA | 1448..1488 | CDD:214542 | 26/39 (67%) | ||
| EGF_CA | 1489..1520 | CDD:214542 | 20/30 (67%) | ||
| TB | 1551..1591 | CDD:459903 | 29/39 (74%) | ||
| EGF_CA | 1608..1640 | CDD:214542 | 27/31 (87%) | ||
| EGF_CA | 1650..1689 | CDD:214542 | 29/39 (74%) | ||
| TB | 1707..1750 | CDD:459903 | 26/42 (62%) | ||
| EGF_CA | 1768..1798 | CDD:429571 | 22/29 (76%) | ||
| EGF_CA | 1810..1842 | CDD:214542 | 19/33 (58%) | ||
| EGF_CA | 1932..1974 | CDD:214542 | 21/41 (51%) | ||
| EGF_CA | 1975..2010 | CDD:238011 | 22/34 (65%) | ||
| EGF_CA | 2015..2045 | CDD:429571 | 20/29 (69%) | ||
| TB | 2070..2113 | CDD:459903 | 26/43 (60%) | ||
| EGF_CA | 2129..2167 | CDD:214542 | 24/40 (60%) | ||
| EGF_CA | 2168..2207 | CDD:214542 | 31/38 (82%) | ||
| TB | <2359..2392 | CDD:459903 | 22/32 (69%) | ||
| vWFA | <2444..2484 | CDD:469594 | 26/39 (67%) | ||
| EGF_CA | 2487..2516 | CDD:429571 | 22/28 (79%) | ||
| EGF_CA | 2526..2568 | CDD:214542 | 22/41 (54%) | ||
| EGF_CA | 2569..>2598 | CDD:214542 | 23/28 (82%) | ||
| EGF_CA | 2609..2640 | CDD:214542 | 20/31 (65%) |